Nrf2 Inhibitors
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master transcription factor that orchestrates the cellular antioxidant response. Under basal conditions, Nrf2 is sequestered in the cytoplasm by its negative regulator, Kelch-like ECH-associated protein 1 (Keap1), which facilitates its ubiquitination and proteasomal degradation. Upon exposure to oxidative or electrophilic stress, the Keap1-Nrf2 interaction is disrupted, allowing Nrf2 to translocate into the nucleus. There, it binds to Antioxidant Response Elements (ARE) in the promoter regions of various genes, inducing the expression of cytoprotective enzymes such as heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase 1 (NQO1), and enzymes involved in glutathione synthesis. While Nrf2 activation is generally considered protective against oxidative damage and inflammation, its role in cancer is complex and often referred to as the 'Nrf2 paradox'. In the early stages of tumorigenesis, Nrf2 acts as a tumor suppressor by protecting cells from DNA damage. However, in established tumors, many cancer cells hijack the Nrf2 pathway to gain a survival advantage.
Overactivation of Nrf2, often due to mutations in Keap1 or Nrf2 itself, provides cancer cells with enhanced resistance to oxidative stress, metabolic reprogramming, and, most importantly, resistance to chemotherapy and radiotherapy. Consequently, Nrf2 inhibitors have emerged as a promising strategy to sensitize Nrf2-addicted tumors to conventional treatments. The development of Nrf2 inhibitors is an active area of preclinical research. These inhibitors can be classified into several types: small molecules that interfere with Nrf2 DNA binding, compounds that accelerate Nrf2 degradation, and those that inhibit Nrf2 transcriptional activity. Notable examples include Brusatol, a natural product that enhances Nrf2 degradation and has shown significant efficacy in sensitizing various cancer cell lines to cisplatin. Another compound, ML385, is a small molecule that binds to the Neh1 domain of Nrf2, preventing its dimerization with small Maf proteins and subsequent binding to the ARE. AEM1 is another inhibitor identified through high-throughput screening that suppresses Nrf2-dependent gene expression.
Despite the potential, no Nrf2 inhibitors have yet been approved for clinical use, and most remain in the early stages of development. One of the primary challenges is the lack of high specificity, as many identified inhibitors like Brusatol also affect global protein synthesis. Furthermore, because Nrf2 is essential for protecting normal cells from oxidative stress, systemic inhibition could lead to significant toxicity in healthy tissues, particularly the liver and lungs. Current research is focused on identifying more selective inhibitors and developing targeted delivery systems to minimize off-target effects. Combination therapy is the most likely clinical application, where Nrf2 inhibitors are used alongside standard chemotherapeutic agents to overcome drug resistance. Additionally, researchers are investigating biomarkers to identify patients with Nrf2-high tumors who would most benefit from this approach. Understanding the structural biology of the Nrf2-Keap1 complex and the various post-translational modifications of Nrf2 continues to provide new opportunities for the design of more effective and safer inhibitors.
